Long-Sheng Chang, Ph.D. :: Nationwide Children's Hospital, Columbus, Ohio

Long-Sheng Chang, PhD

Long-Sheng  Chang, PhD

Contact Information

The Research Institute at Nationwide Children's Hospital
700 Children's Drive
Columbus, Ohio 43205 [ map ]
PH: (614) 722-2700
E-mail Me

Biography

Long-Sheng Chang, Ph.D., is a Principal Investigator at the Center for Childhood Cancer at The Research Institute at Nationwide Children’s Hospital. He is a Professor in the Department of Pediatrics, The Ohio State University College of Medicine. Dr. Chang’s research program focuses on the role of the Neurofibromatosis 2 (NF2) tumor suppressor gene during development and tumorigenesis, therapeutic development for Neurofibromatosis type 2 (NF2)-associated vestibular schwannoma and meningioma, and investigation of a link between NF2 and breast cancer.

Gender:

  • Male

Languages Spoken:

  • English

Research Interests

Research Center:

Areas of Interest:

  • The main focus of Dr. Chang’s laboratory is to better understand how tumor suppressor genes are regulated and function during development and tumorigenesis. His laboratory is interested in the function and regulation of the neurofibromatosis type 2 (NF2) tumor suppressor gene. Recent studies show that mutations in the NF2 gene are associated with vestibular schwannoma formation. Together with D. Bradley Welling, MD, PhD, Department of Otolaryngology, Dr. Chang is studying the molecular mechanism by which the NF2 gene acts to prevent tumor formation. In addition, the laboratory is examining the regulation of the NF2 gene during nervous system development and the role of the NF2 protein during neural tube closure and neural crest cell migration. Dr. Chang’s laboratory is also elucidating the regulatory mechanisms governing the expression of the retinoblastoma gene product (Rb) and related p107 genes. Dr. Chang’s group is examining how the Rb-family suppressor proteins and E2F-family transcription factors interplay to modulate gene expression during cell cycle and development. Additionally, his laboratory is studying the neural-specific serotonin 5-HT2C receptor, which plays important roles in epilepsy and obesity.

Education and Training

Undergraduate School

  • National Taiwan University
    Date Completed: 06/30/1978

Graduate School

  • National Taiwan University, Graduate Institute of Electric Engineering
    Date Completed: 06/30/1979

Post Doctoral

  • New Jersey Medical School, University of Medicine and Dentistry of New Jersey
    Date Completed: 06/30/1984

Post Doctoral

  • Princeton University
    Date Completed: 06/30/1990

Professional Experience

2007–present

  • Professor, Department of Pediatrics, The Ohio State University College of Medicine, and Center for Childhood Cancer, Children’s Research Institute, Children’s Hospital, Columbus, OH

2007–present

  • Adjunct Professor, Departments of Molecular Cellular Biochemistry, Pathology, Otolaryngology, and Vet. Biosci., The Ohio State University, Columbus, OH

2006–present

  • Senate Member, University Senate’s Committee on Academic Misconduct, The Ohio State University, Columbus, OH

2001–present

  • Otolaryngology Fellow Training Program Committee, Department of Otolaryngology, The Ohio State University College of Medicine, Columbus, OH

2001–present

  • Judge, Otolaryngology Resident and Fellow  Presentations at the Annual Otolaryngology Alumni Symposium, Department of Otolaryngology, The Ohio State University College of Medicine, Columbus, OH

1996–present

  • Institutional Animal Care and Use Committee, Children’s Hospital Research Foundation, Children's Hospital, Columbus, OH

1995–present

  • Institutional Biosafety Recombinant DNA Committee, The Ohio State University Research Foundation, The Ohio State University, Columbus, OH

1995–present

  • Medical Staff Committee on Comprehensive Cancer Care, Children's Hospital, Columbus, OH

1994–present

  • Appointment to Category III Service on the Graduate Faculty in Molecular Cellular Development Biology Program and Ohio State Biochemistry Program, The Ohio State University, Columbus, OH

1993–present

  • Oncology Training Grant Committee, Division of Hematology-Oncology, Department of Internal Medicine, The Ohio State University College of Medicine, Columbus, OH

1990–present

  • Member, Molecular, Cellular, and Developmental Biology (MCDB) Program and Ohio State Biochemistry Program (OSBP), The Ohio State University, Columbus, OH

2007–2007

  • Peer-Review Scientific Reviewer, The Department of Defense Post-Traumatic Stress Disorder/Traumatic Brain Injury (PTSD/TBI) Research Program Panel 4

2007–2007

  • Peer-Review Online Reviewer, The Department of Defense Post-Traumatic Stress Disorder/Traumatic Brain Injury (PTSD/TBI) Research Program Panel 2

2006–2006

  • Referee, Grants Committee, Medical Research Council, UK

2005–2005

  • 2005 Peer-Review Panel Member, Cancer Research Program, The US Army Medical Research and Material Command (USAMRMC) Congressionally Directed Medical Research Program (CDMRP)

2005–2005

  • Referee, Project Grants Committee, Cancer Research UK

2003–2007

  • Adjunct Associate Professor, Department of Veterinary Biosciences, The Ohio State University, Columbus, OH

2002–2003

  • Organizer, the Center for Childhood Cancer Bi-monthly Research Meeting, Children’s Research Institute, Columbus, OH

2001–2007

  • Adjunct Associate Professor, Department of Otolaryngology, The Ohio State University College of Medicine, Columbus, OH

1999–1999

  • Organizer, 11th Annual Stone Lab Meeting, The Ohio State University Comprehensive Cancer Center Molecular Biology & Human Cancer Genetics Program, F.T. Stone Laboratory, The Ohio State University Put-in-Bay Campus, OH

1998–2007

  • Adjunct Associate Professor, Department of Pathology, The Ohio State University College of Medicine, Columbus, OH

1998–2003

  • Graduate Admission Committee, Ohio State Biochemistry Program, The Ohio State University, Columbus, OH

1997–1998

  • Rotation Research Advisory Committee, Molecular, Cellular, & Developmental Biology Program, The Ohio State University, Columbus, OH

1996–2007

  • Adjunct Associate Professor, Department of Molecular Cellular Biochemistry (former Medical Biochemistry), The Ohio State University College of Medicine, Columbus, OH

1996–2007

  • Associate Professor, Department of Pediatrics, Children's Hospital and The Ohio State University, Columbus, OH

1995–1996

  • Laboratory Director, The Ohio State University Comprehensive Cancer Center Transgenic Mouse Facility at Children's Hospital, The Ohio State University, Columbus, OH

1995–1996

  • Design Task Force for Wexner Institute for Pediatric Research, Children’s Hospital, Columbus, OH

1994–1995

  • Gene Therapy Task Force, College of Medicine, The Ohio State University, Columbus, OH

1993–2006

  • Graduate Studies Committee, Molecular Cellular Development Biology Program, The Ohio State University, Columbus, OH

1993–1996

  • Transgenic Advisory Committee, Biotechnology Center, The Ohio State University, Columbus, OH

1992–1995

  • Strategic Planning Task Force Committee, Children's Hospital Research Foundation, Children's Hospital, Columbus, OH

1992–1995

  • Operation Committee, Children's Hospital Research Foundation, Children's Hospital, Columbus, OH

1991–1996

  • Adjunct Assistant Professor, Department of Medical Biochemistry, The Ohio State University College of Medicine, Columbus, OH

1991–1996

  • Program Committee, Children's Hospital Research Foundation, Children's Hospital, Columbus, OH

1991–1995

  • Laboratory Director, The Ohio State University/Children's Hospital Transgenic Mouse Facility, Columbus, OH

1990–1996

  • Assistant Professor, Department of Pediatrics, Children's Hospital and The Ohio State University College of Medicine, Columbus, OH

1988–1990

  • Research Staff Member, Department of Molecular Biology, Princeton University, Princeton, NJ.  Mentor: Dr. Thomas E. Shenk

1985–1987

  • Leukemia Society Research Fellow, Leukemia Society of America, Advisor: Dr. Thomas E. Shenk, Professor, Howard Hughes Professor, and Member of National Academy of Sciences

1985–1985

  • Research Associate, Department of Molecular Biology, Princeton University, Princeton, NJ.  Advisor: Dr. Thomas E. Shenk, Professor and Member of National Academy of Sciences, Department of Molecular Biology, Princeton University

1984–1984

  • Research Associate, Department of Microbiology, New Jersey Medical School, UMDNJ, Newark, NJ.  Advisor: Dr. Giampiero di Mayorca, Professor and Chairman

1979–1984

  • Ph.D. Research, Department of Microbiology, New Jersey Medical School, UMDNJ, Newark, NJ.  Advisor: Dr. Giampiero di Mayorca, Professor and Chairman

1978–1979

  • Medical Technologist, Department of Medical Technology, National Taiwan University Hospital, Taipei, Taiwan, R.O.C.

1977–1978

  • Undergraduate Thesis Research.  Advisor:  Dr. C.-S. Yang, M.D., Professor and Director, Graduate Institute of Bacteriology, College of Medicine, National Taiwan University, Taipei, Taiwan, R.O.C.

Publications

  • Spear SA, Burns SS, Oblinger JL, Ren Y, Pan L, Kinghorn AD, Welling DB, Chang LS. 2013. Natural compounds as potential treatments of NF2-deficient schwannoma and meningioma: cucurbitacin D and goyazensolide.  Otol Neurotol. Vol. 34, no. 8. (October): 1519-1527.
  • Petrilli A, Copik A, Posadas M, Chang LS, Welling DB, Giovannini M, Fernández-Valle C. 2013. LIM domain kinases as potential therapeutic targets for neurofibromatosis type 2.  Oncogene. Vol. 32, no. August: eEpub ahead of print.
  • Burns,Sarah,S; Akhmametyeva,Elena,M; Oblinger,Janet,L; Bush,Matthew,L; Huang,Jie; Senner,Volker; Chen,Ching-Shih; Jacob,Abraham; Welling,D,Bradley; Chang,Long-Sheng. 2013. Histone Deacetylase Inhibitor AR-42 Differentially Affects Cell-cycle Transit in Meningeal and Meningioma Cells, Potently Inhibiting NF2-Deficient Meningioma Growth.  CANCER RESEARCH. Vol. 73, no. 2. (January): 792-803.
  • Wang,Yuan; Kim,Edward; Wang,Xiaojing; Novitch,Bennett,G; Yoshikawa,Kazuaki; Chang,Long-Sheng; Zhu,Yuan. 2012. ERK Inhibition Rescues Defects in Fate Specification of Nf1-Deficient Neural Progenitors and Brain Abnormalities.  CELL. Vol. 150, no. 4. (August): 816-830.
  • Bush, M.L., S.S. Burns, J. Oblinger, S. Davletova, L.-S. Chang, D.B. Welling, and A. Jacob. 2012. Treatment of Vestibular Schwannoma Cells with ErbB inhibitors.  Otology & Neurotology. Vol. 33, no. 2. (February): 244-257.
  • Jacob, A, Oblinger, J, Bush, M.L., Brendel, V., Santarelli, G., Chaudhury, A.R., Kulp, S., La Perle, K.M., Chen, C.-S., Chang, L.-S., Welling, D.B. 2012. Preclinical Validation of AR42, a Novel Histone Deacetylase Inhibitor, as Treatment for Vestibular Schwannomas.  Laryngoscope. Vol. 122, no. January: 174-189.
  • Yates, C., D.B. Welling, L.-S. Chang. 2011. Research Advances in Therapeutics for Neurofibromatosis Type 2-Associated Vestibular Schwannomas.  Advances in Neurofibromatosis Research. Vol. 1, no. August: e1.
  • Yates, C., D.B. Welling, L.-S. Chang. 2011. Research Advances in Therapeutics for Neurofibromatosis Type 2-Associated Vestibular Schwannomas. In Advances in Neurofibromatosis Research. Edited by K.S. Cunha and M. Geller. Hauppauge: Nova Science Publishers, Inc..
  • Bush, M.L., J. Oblinger, V. Brendel, G. Santarelli, C. Hrelec, J. Davis, J. Huang, E.M. Akhmametyeva, S.S. Burns, S. Kulp, C.-S. Chen, M. Giovannini, L.-S. Chang, D.B. Welling, and A. Jacob. 2011. HDAC42, A Novel Histone Deacetylase Inhibitor, as a Potential Therapy for Vestibular Schwannomas and Meningiomas.  Neuro-Oncology. Vol. 13, no. 9. (May): 983-999.
  • Dubatolova,T,D; Dorogova,N,V; Omel'yanchuk,L,V; Chang,L-Sh. 2011. Duration of the cell cycle phases in mutants for the tumor suppressor Merlin in Drosophila melanogaster.  RUSSIAN JOURNAL OF GENETICS. Vol. 47, no. 4. (April): 404-408.
  • Akhmametyeva, E.M., S.S. Burns, J. Huang, A. Ray-Chaudhury, D.B. Welling, L.-S. Chang. Formation of Malignant Peripheral Nerve Sheath Tumor and Schwannoma in the NF2 Promoter-T transgenic mice.  Int. J. Cancer.
  • Yudina,O,S; Golovnina,K,A; Dorogova,N,V; Kopyl,S,A; Bolobolova,E,U; Dubatolova,T,D; Shilova,I,E; Omelyanchuk,L,V; Blinov,A,G; Chang,L-Sh. 2010. The role of the functional sites of the merlin tumor suppressor in Drosophila Spermatogenesis.  RUSSIAN JOURNAL OF GENETICS. Vol. 46, no. 10. (October): 1214-1216.
  • Iudina,O,S; Golovnina,K,A; Dorogova,N,V; Kopyl,S,A; Bolobolova,E,U; Dubatolova,T,D; Shilova,I,É; Omel'ianchuk,L,V; Blinov,A,G; Chang,L,Sh. 2010. [The role of the functional sites of the Merlin tumor suppressor in Drosophila spermatogenesis].  Genetika. Vol. 46, no. 10. (October): 1376-1378.
  • Chai,Guolin; Liu,Ning; Ma,Junrong; Li,Hua; Oblinger,Janet,L; Prahalad,Agasanur,K; Gong,Meng; Chang,Long-Sheng; Wallace,Margaret; Muir,David; Guha,Abhijit; Phipps,Roger,J; Hock,Janet,M; Yu,Xijie. 2010. MicroRNA-10b regulates tumorigenesis in neurofibromatosis type 1.  CANCER SCIENCE. Vol. 101, no. 9. (September): 1997-2004.
  • Popov,B,V; Watt,S,M; ROZANOV,I,M; CHANG,L,S. 2010. [A pocket pRb mutation induces the increase in its affinity to E2F4 coupled with activation of muscle differentiation].  Molekuliarnaia biologiia. Vol. 44, no. 2. (March): 323-334.
  • Kopyl,S,A; Dorogova,N,V; Akhmametyeva,E,M; Omelyanchuk,L,V; Chang,L-S. 2010. Drosophila melanogaster gene Merlin interacts with the clathrin adaptor protein gene lap.  RUSSIAN JOURNAL OF GENETICS. Vol. 46, no. 3. (March): 276-282.
  • Kopyl,S,A; Dorogova,N,V; Akhmamet'eva,E,M; Omel'ianchuk,L,V; CHANG,L,S. 2010. [Drosophila melanogaster gene Merlin interacts with the clathrin adaptor protein gene lap].  Genetika. Vol. 46, no. 3. (March): 314-320.
  • Dubatolova,T,D; Kopyl,S,A; Bulgakova,N,A; Dorogova,N,V; Omelyanchuk,L,V; Chang,L-Sh. 2010. Effect of mutations in Drosophila melanogaster tumor suppressor Merlin on proliferation and differentiation of wing cells.  RUSSIAN JOURNAL OF GENETICS. Vol. 46, no. 2. (February): 164-169.
  • Dubatolova,T,D; Kopyl,S,A; Bulgakova,N,A; Dorogova,N,V; Omel'ianchuk,L,V; Chang,L,Sh. 2010. [Effect of mutations in Drosophila melanogaster tumor suppressor Merlin on proliferation and differentiation of wing cells].  Genetika. Vol. 46, no. 2. (February): 187-193.
  • Iudina, O.S., K.A. Golovina, N.V. Dorogova, S.A. Kopyl, E.U. Bolobolova, T.D. Dubatolova, I.E. Shilova, L.V. Omelyanchuk, A.G. Blinov, L.-S. Chang. 2010. The Role of the Functional Sites of the Merlin Tumor Suppressor in Drosophila Spermatogenesis.  Genetika. Vol. 46, no. January: 1214-1216.
  • Chai, G., N., Liu, J. Ma, H. Li, J.L. Oblinger, A.K. Prahalad, M. Gong, L.-S. Chang, M. Wallace, D. Muir, A. Guha, R.J. Phipps, J.M. Hock, X. Yu. 2010. MicroRNA-10b Regulates Tumorigenesis in Neurofibromatosis Type 1.  Cancer Science. Vol. 101, no. January: 1997-2004.
  • Dubatolova, T.D., S.A. Kopyl, N.A. Bulgakova, N.V. Dorogova, L.V. Omelyanchuk, L.-S. Chang. 2010. Effect of Mutations in Drosophila melanogaster Tumor Suppressor Merlin on Proliferation and Differentiation of Wing Cells.  Genetika. Vol. 46, no. January: 164-169.
  • Yates, C., D.B. Welling, L.-S. Chang. 2010. Research Advances in Therapeutics for Neurofibromatosis Type 2-Associated Vestibular Schwannomas. In Advances in Neurofibromatosis Research, K.S. Cunha and M. Geller (Eds.). Nova Science Publishers, Inc., Hauppauge, N.Y. Hauppauge, NY: Nova Science Publishers, Inc..
  • Kopyl, S.A., N.V. Dorogova, E.M. Akhmametyeva, L.V. Omelyanchuk, and L.-S. Chang. 2010. Drosophila melanogaster Gene Merlin Interacts with the Clathrin Adaptor Protein Gene lap.  Genetika. Vol. 46, no. January: 276-282.
  • Popov, B.V., S.M. Watt, J.M. Rosanov, and L.-S. Chang. 2010. A Structural Pocket Mutation of pRb Increases Its Affinity for E2F4, Which Is Coupled with Activation of Muscle Differentiation.  Mol. Biol.. Vol. 44, no. January: 287-297.
  • Chen KC; Chang LS. 2009. Arachidonic acid-induced apoptosis of human neuroblastoma SK-N-SH cells is mediated through mitochondrial alteration elicited by ROS and Ca(2+)-evoked activation of p38alpha MAPK and JNK1.  Toxicology. Vol. 262, no. 3. (August): e199.
  • Lee TX; Packer MD; Huang J; Akhmametyeva EM; Kulp SK; Chen CS; Giovannini M; Jacob A; Welling DB; Chang LS. 2009. Growth inhibitory and anti-tumour activities of OSU-03012, a novel PDK-1 inhibitor, on vestibular schwannoma and malignant schwannoma cells.  European Journal Of Cancer (Oxford, England: 1990). Vol. 45, no. 9. (June): e1709.
  • Omelyanchuk, L.V., J.A. Pertseva, S.S. Burns, and L.-S. Chang. 2009. Evolution and Origin of HRS, a Protein Interacting with Merlin, the Neurofibromatosis 2 Gene Product.  Gene Regul. Syst. Biol. Vol. 3, no. January: 143-157.
  • Welling, D.B., M.D. Packer, and L.-S. Chang. 2009. Tumor Biology. In Surgery of the Ear, 6th edition. Glasscock M.E., Gulya J.E., Minor L.B., and Poe D.S. (Eds.), B.C. Decker Inc., Hamilton, Ontario, CA. Hamilton, Ontario, CA: B.C. Decker Inc..
  • Chang LS; Welling DB. 2009. Molecular biology of vestibular schwannomas.  Methods In Molecular Biology (Clifton, N.J.). Vol. 493, no. January: 163-177.
  • Welling, D.B., M.D. Packer, and L.-S. Chang. 2009. Tumor Biology. In Surgery of the Ear, 6th edition. Edited by Glasscock M.E., Gulya J.E., Minor L.B., and Poe D.S. Hamilton, ON: B.C. Decker Inc.
  • Popov, B., A. Zaichik, S. Watt, and L.-S. Chang. 2009. A “Pocketâ€? pRb Mutation Induces the Increase in Its Affinity to E2F4 Coupled with Activation of Muscle Differentiation.  Russ. J. Mol. Biol..
  • Lee, T., M.D. Packer, J. Huang, E.M. Akhmametyeva, A. Jacob, S. Kulp, C.-S. Chen, D.B. Welling, and L.-S. Chang. 2009. Growth Inhibitory and Anti-Tumor Activities of OSU-03012, a Novel PDK1 Inhibitor, on Vestibular Schwannoma and Malignant Schwannoma Cells.  Eur. J. Cancer. Vol. 45, no. January: 1709-1720.
  • Kopyl,S,A; Dorogova,N,V; Baimak,T,Yu; Chang,L-S; Omelyanchuk,L,V. 2008. Role of the porcupine Gene in the Development of the Wing Imaginal Disk of Drosophila melanogaster.  RUSSIAN JOURNAL OF GENETICS. Vol. 44, no. 11. (November): 1290-1295.
  • Kopyl SA; Dorogova NV; Baimak TIu; Chang LS; Omel'ianchuk LV. 2008. [Role of the porcupine gene in the development of the wing imaginal disk of Drosophila melanogaster].  Genetika. Vol. 44, no. 11. (November): e1486.
  • Jacob A; Lee TX; Neff BA; Miller S; Welling B; Chang LS. 2008. Phosphatidylinositol 3-kinase/AKT pathway activation in human vestibular schwannoma.  Otology & Neurotology: Official Publication Of The American Otological Society, American Neurotology Society [And] European Academy Of Otology And Neurotology. Vol. 29, no. 1. (January): 58-68.
  • Kopyl SA, Dorogova NV, Baymak TY, Chang LS, Omelyanchuk LV. 2008. The Role of Porcupine Gene In the Development of Wing Imaginal Disc of Drosophila Melanogaster.  Genetica. Vol. 44, no. January: 1-7.
  • Dorogova NV, Akhmameteva EM, Kopyl SA, Gubanova NV, Yudina OS, Omelyanchuk LV, Chang LS. 2008. The Role of Drosophila Merlin in Spermatogenesis.  BMC Cell Biol.. Vol. 9, no. January: 1-15.
  • Jacob A, Lee TX, Neff BA, Miller S, Welling DB, Chang LS. 2008. Activation of the AKT Pathway in Human Vestibular Schwannomas.  Otol. Neurotol.. Vol. 29, no. January: 58-68.
  • Jacob A; Lee TX; Neff BA; Miller S; Welling B; Chang LS. 2008. Phosphatidylinositol 3-kinase/AKT pathway activation in human vestibular schwannoma.  Otology & Neurotology: Official Publication Of The American Otological Society, American Neurotology Society [And] European Academy Of Otology And Neurotology. Vol. 29, no. 1. (January): e58.
  • Yudina OS, Gusachenko AM, Akhmameteva Em, Omelyanchuk LV, Chang LS. 2008. Chromosome non-disjunction in tumor-suppressor Merlin mutant strains.  J. Genet.. Vol. 44, no. January: 357-359.
  • Welling, D.B., M.D. Packer, E.M. Akhmametyeva, and L.-S. Chang. 2008. The Biology and Genetics of Vestibular Schwannomas. In Surgery of the Cerebellopontine Angle, Bambakidis, N., C. Megerian, and R. Spetzler (Eds), B.C. Decker, Inc., Hamilton, Ontario, CA. Hamilton, Ontario, CA: B.C. Decker, Inc.
  • Chang LS, Welling DB. 2008. Biology of Vestibular Schwannomas. In Auditory/Vestibular Research. Edited by Sokolowski, B.. Totowa: The Humana Press.
  • Welling DB; Packer MD; Chang LS. 2007. Molecular studies of vestibular schwannomas: a review.  Current Opinion In Otolaryngology & Head And Neck Surgery. Vol. 15, no. 5. (October): e341.
  • Welling DB, Packer MD, Chang LS. 2007. Molecular studies of vestibular schwannomas: a review.  Current Opinion in Otolaryngology & Head and Neck Surgery. Vol. 15, no. 5. (January): 341-346.
  • D.B.Welling, M.D. Packer, E.M. Akhmametyeva, Long-Sheng Chang. 2007. The Biology and Genetics of Vestibular Schwannomas. In Tumors of the Cerebellopontine Angle. Edited by NC Bambakidis, Porter Megerian, RF Spetzler. Hamiliton, ON: B.C. Decker, Inc.
  • Welling, D Bradley; Packer, Mark, D; Chang, Long-Sheng. 2007. Molecular studies of vestibular schwannomas: a review.  Current opinion in otolaryngology & head and neck surgery. Vol. 15, no. 5. (January).
  • Chang LS; Jacob A; Lorenz M; Rock J; Akhmametyeva EM; Mihai G; Schmalbrock P; Chaudhury AR; Lopez R; Yamate J; John MR; Wickert H; Neff BA; Dodson E; Welling DB. 2006. Growth of benign and malignant schwannoma xenografts in severe combined immunodeficiency mice.  The Laryngoscope. Vol. 116, no. 11. (November): 2018-2026.
  • Akhmametyeva EM; Mihaylova MM; Luo H; Kharzai S; Welling DB; Chang LS. 2006. Regulation of the neurofibromatosis 2 gene promoter expression during embryonic development.  Developmental Dynamics: An Official Publication Of The American Association Of Anatomists. Vol. 235, no. 10. (October): e2771.
  • Neff BA; Oberstien E; Lorenz M; Chaudhury AR; Welling DB; Chang LS. 2006. Cyclin D(1) and D(3) expression in vestibular schwannomas.  The Laryngoscope. Vol. 116, no. 3. (March): 423-426.
  • Neff BA; Welling DB; Akhmametyeva E; Chang LS. 2006. The molecular biology of vestibular schwannomas: dissecting the pathogenic process at the molecular level.  Otology & Neurotology: Official Publication Of The American Otological Society, American Neurotology Society [And] European Academy Of Otology And Neurotology. Vol. 27, no. 2. (February): 197-208.
  • Jiang Y; Lo W; Akhmametyeva EM; Chang LS. 2006. Over-expression of p73beta results in apoptotic death of post-mitotic hNT neurons.  Journal Of The Neurological Sciences. Vol. 240, no. 1-2. (January): 1-6.
  • Golovnina K; Blinov A; Akhmametyeva EM; Omelyanchuk LV; Chang LS. 2005. Evolution and origin of merlin, the product of the Neurofibromatosis type 2 (NF2) tumor-suppressor gene.  BMC Evolutionary Biology. Vol. 5, no. December: e69.
  • Popov B; Chang LS; Serikov V. 2005. Cell cycle-related transformation of the E2F4-p130 repressor complex.  Biochemical And Biophysical Research Communications. Vol. 336, no. 3. (October): 762-769.
  • Xu Z; Huang S; Chang LS; Agulnick AD; Brandt SJ. 2003. Identification of a TAL1 target gene reveals a positive role for the LIM domain-binding protein Ldb1 in erythroid gene expression and differentiation.  Molecular And Cellular Biology. Vol. 23, no. 21. (November): 7585-7599.
  • Lasak JM; Welling DB; Akhmametyeva EM; Salloum M; Chang LS. 2002. Retinoblastoma-cyclin-dependent kinase pathway deregulation in vestibular schwannomas.  The Laryngoscope. Vol. 112, no. 9. (September): e1555.
  • Lasak,J,M; Welling,B; Akhmametyeva,E,M; Salloum,M; Chang,L,S. 2002. Retinoblastoma - Cyclin-dependent kinase pathway deregulation in vestibular schwannomas. In Annual Meeting of the Middle-Section of the Triological-Society
  • Welling DB; Lasak JM; Akhmametyeva E; Ghaheri B; Chang LS. 2002. cDNA microarray analysis of vestibular schwannomas.  Otology & Neurotology: Official Publication Of The American Otological Society, American Neurotology Society [And] European Academy Of Otology And Neurotology. Vol. 23, no. 5. (September): 736-748.
  • Podust VN; Chang LS; Ott R; Dianov GL; Fanning E. 2002. Reconstitution of human DNA polymerase delta using recombinant baculoviruses: the p12 subunit potentiates DNA polymerizing activity of the four-subunit enzyme.  The Journal Of Biological Chemistry. Vol. 277, no. 6. (February): 3894-3901.
  • Chang LS; Akhmametyeva EM; Wu Y; Zhu L; Welling DB. 2002. Multiple transcription initiation sites, alternative splicing, and differential polyadenylation contribute to the complexity of human neurofibromatosis 2 transcripts.  Genomics. Vol. 79, no. 1. (January): 63-76.
  • Welling DB; Akhmametyeva EM; Daniels RL; Lasak JM; Zhu L; Miles-Markley BA; Chang LS. 2000. Analysis of the human neurofibromatosis type 2 gene promoter and its expression.  Otolaryngology--Head And Neck Surgery: Official Journal Of American Academy Of Otolaryngology-Head And Neck Surgery. Vol. 123, no. 4. (October): e413.
  • Reshetnikova G; Barkan R; Popov B; Nikolsky N; Chang LS. 2000. Disruption of the actin cytoskeleton leads to inhibition of mitogen-induced cyclin E expression, Cdk2 phosphorylation, and nuclear accumulation of the retinoblastoma protein-related p107 protein.  Experimental Cell Research. Vol. 259, no. 1. (August): 35-53.
  • Mao Y; Okada S; Chang LS; Muller MT. 2000. p53 dependence of topoisomerase I recruitment in vivo.  Cancer Research. Vol. 60, no. 16. (August): 4538-4543.
  • Welling DB; Chang LS. 2000. All in a name: schwannomin versus merlin.  The American Journal Of Otology. Vol. 21, no. 2. (March): e289.
  • Karacay B; Chang LS. 1999. Induction of erythrocyte protein 4.2 gene expression during differentiation of murine erythroleukemia cells.  Genomics. Vol. 59, no. 1. (July): 6-17.
  • Zhu L; Kahwash SB; Chang LS. 1998. Developmental expression of mouse erythrocyte protein 4.2 mRNA: evidence for specific expression in erythroid cells.  Blood. Vol. 91, no. 2. (January): 695-705.
  • Lee Y; Chen Y; Chang LS; Johnson LF. 1997. Inhibition of mouse thymidylate synthase promoter activity by the wild-type p53 tumor suppressor protein.  Experimental Cell Research. Vol. 234, no. 2. (August): 270-276.
  • Zhao L; Chang LS. 1997. The human POLD1 gene. Identification of an upstream activator sequence, activation by Sp1 and Sp3, and cell cycle regulation.  The Journal Of Biological Chemistry. Vol. 272, no. 8. (February): 4869-4882.
  • Xie E; Zhu L; Zhao L; Chang LS. 1996. The human serotonin 5-HT2C receptor: complete cDNA, genomic structure, and alternatively spliced variant.  Genomics. Vol. 35, no. 3. (August): e551.
  • Chang LS; Zhao L; Zhu L; Chen ML; Lee MY. 1995. Structure of the gene for the catalytic subunit of human DNA polymerase delta (POLD1).  Genomics. Vol. 28, no. 3. (August): e411.
  • Zhu L; Zhu L; Xie E; Chang LS. 1995. Differential roles of two tandem E2F sites in repression of the human p107 promoter by retinoblastoma and p107 proteins.  Molecular And Cellular Biology. Vol. 15, no. 7. (July): 3552-3562.
  • Karacay B; Xie E; Chang LS. 1995. The murine erythrocyte protein-4.2-encoding gene: similarities and differences in structure and expression from its human counterpart.  Gene. Vol. 158, no. 2. (June): 253-256.
  • Zhang SJ; Zeng XR; Zhang P; Toomey NL; Chuang RY; Chang LS; Lee MY. 1995. A conserved region in the amino terminus of DNA polymerase delta is involved in proliferating cell nuclear antigen binding.  The Journal Of Biological Chemistry. Vol. 270, no. 14. (April): 7988-7992.
  • Sung LA; Chien S; Fan YS; Lin CC; Lambert K; Zhu L; Lam JS; Chang LS. 1992. Human erythrocyte protein 4.2: isoform expression, differential splicing, and chromosomal assignment.  Blood. Vol. 79, no. 10. (May): 2763-2770.
  • Yang CL; Chang LS; Zhang P; Hao H; Zhu L; Toomey NL; Lee MY. 1992. Molecular cloning of the cDNA for the catalytic subunit of human DNA polymerase delta.  Nucleic Acids Research. Vol. 20, no. 4. (February): 735-745.
  • Parks CL; Chang LS; Shenk T. 1991. A polymerase chain reaction mediated by a single primer: cloning of genomic sequences adjacent to a serotonin receptor protein coding region.  Nucleic Acids Research. Vol. 19, no. 25. (December): 7155-7160.
  • Shi Y; Seto E; Chang LS; Shenk T. 1991. Transcriptional repression by YY1, a human GLI-Krüppel-related protein, and relief of repression by adenovirus E1A protein.  Cell. Vol. 67, no. 2. (October): 377-388.
  • Yan,D,H; CHANG,L,S; Hung,M,C. 1991. REPRESSED EXPRESSION OF THE HER-2/C-ERBB-2 PROTOONCOGENE BY THE ADENOVIRUS E1A GENE-PRODUCTS.  ONCOGENE. Vol. 6, no. 2. (February): 343-345.
  • Yu,D,H; Suen,T,C; Yan,D,H; CHANG,L,S; Hung,M,C. 1990. TRANSCRIPTIONAL REPRESSION OF THE NEU PROTOONCOGENE BY THE ADENOVIRUS-5 E1A GENE-PRODUCTS.  PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. Vol. 87, no. 12. (June): 4499-4503.
  • CHANG,L,S; Shenk,T. 1990. THE ADENOVIRUS DNA-BINDING PROTEIN STIMULATES THE RATE OF TRANSCRIPTION DIRECTED BY ADENOVIRUS AND ADENOASSOCIATED VIRUS PROMOTERS.  JOURNAL OF VIROLOGY. Vol. 64, no. 5. (May): 2103-2109.
  • Sung,L,A; Chien,S; CHANG,L,S; Lambert,K; Bliss,S,A; Bouhassira,E,E; Nagel,R,L; Schwartz,R,S; Rybicki,A,C. 1990. MOLECULAR-CLONING OF HUMAN PROTEIN-4.2 - A MAJOR COMPONENT OF THE ERYTHROCYTE-MEMBRANE.  PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. Vol. 87, no. 3. (February): 955-959.
  • Samulski,R,J; CHANG,L,S; Shenk,T. 1989. HELPER-FREE STOCKS OF RECOMBINANT ADENO-ASSOCIATED VIRUSES - NORMAL INTEGRATION DOES NOT REQUIRE VIRAL GENE-EXPRESSION.  JOURNAL OF VIROLOGY. Vol. 63, no. 9. (September): 3822-3828.
  • CHANG,L,S; Shi,Y; Shenk,T. 1989. ADENO-ASSOCIATED VIRUS P5 PROMOTER CONTAINS AN ADENOVIRUS E1A-INDUCIBLE ELEMENT AND A BINDING-SITE FOR THE MAJOR LATE TRANSCRIPTION FACTOR.  JOURNAL OF VIROLOGY. Vol. 63, no. 8. (August): 3479-3488.
  • Samulski,R,J; CHANG,L,S; Shenk,T. 1987. A RECOMBINANT PLASMID FROM WHICH AN INFECTIOUS ADENOASSOCIATED VIRUS GENOME CAN BE EXCISED INVITRO AND ITS USE TO STUDY VIRAL REPLICATION.  JOURNAL OF VIROLOGY. Vol. 61, no. 10. (October): 3096-3101.
  • CHANG,L,S; Pan,S; Pater,M,M; DIMAYORCA,G. 1985. DIFFERENTIAL REQUIREMENT FOR SV40 EARLY GENES IN IMMORTALIZATION AND TRANSFORMATION OF PRIMARY RAT AND HUMAN-EMBRYONIC CELLS.  VIROLOGY. Vol. 146, no. 2. (January): 246-261.
  • Hutchinson,N,I; CHANG,L,S; Pater,M,M; Bouck,N; Shenk,T,E; DIMAYORCA,G. 1985. CHARACTERIZATION OF A NEW SIMIAN-VIRUS 40 MUTANT, TSA3900, ISOLATED FROM DELETION MUTANT TSA1499.  JOURNAL OF VIROLOGY. Vol. 53, no. 3. (January): 814-821.
  • CHANG,L,S; Pater,M,M; Hutchinson,N,I; DIMAYORCA,G. 1984. TRANSFORMATION BY PURIFIED EARLY GENES OF SIMIAN VIRUS-40.  VIROLOGY. Vol. 133, no. 2. (January): 341-353.
  • Pater,A; Pater,M,M; CHANG,L,S; Slawin,K; DIMAYORCA,G. 1983. MULTIPLE ORIGINS OF THE COMPLEMENTARY DEFECTIVE GENOMES OF RF AND ORIGIN PROXIMAL SEQUENCES OF GS, 2 HUMAN PAPOVAVIRUS ISOLATES.  VIROLOGY. Vol. 131, no. 2. (January): 426-436.
Nationwide Children's Hospital
700 Children's Drive Columbus, Ohio 43205 614.722.2000